EU cancer drugs rejection shows contrasts with FDAEurope’s expert medicines panel has rejected Puma Biotechnology’s breast cancer drug neratinib, citing limitations in its efficacy and safety Share XEU cancer drugs rejection shows contrasts with FDAhttps://pharmaphorum.com/news/eu-rejection-cancer-drugs-shows-differences-fda/
